Multiple sclerosis and COVID-19: A retrospective study in Iran.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
08
2022
accepted:
10
03
2023
entrez:
23
3
2023
pubmed:
24
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Previous studies suggested a higher rate of COVID-19 infection in patients with multiple sclerosis than in the general population, and limited studies addressed the impact of COVID-19 and its vaccination in patients with multiple sclerosis in Iran. We decided to investigate the factors associated with COVID-19 infection, the effects and side effects of the COVID-19 vaccination in patients with multiple sclerosis (MS). We used the data of the patients with multiple sclerosis registered in a referral clinic in Kerman, one of the large cities in Iran (a population of 537,000 inhabitants), to explore the association between demographic variables, the history of COVID-19 vaccination, and the clinical outcomes. Of the 367 participants in this study, 88.3% received the COVID-19 vaccine, 35.4% were confirmed COVID-19 cases, and the incidence of COVID-19 was much higher before vaccination (24.5% before vaccination versus 10.1% after vaccination). The multivariable logistic regression model showed that male gender (OR = 2.64, 95% confidence interval: 1.21, 5.74) and current employment (OR = 3.04, 95% confidence interval: 1.59, 5.80) were associated with an increased risk of COVID-19. The only factor associated with the adverse effects of COVID-19 vaccination was the type of vaccine (AstraZeneca). Our findings showed that the vaccination protected MS cases considerably against COVID-19. In addition, the side effects of the vaccines were not noticeably high in these cases as well. Among all COVID-19 vaccines, AstraZeneca had the most common side effects, so people must be aware of them before vaccination. The male gender and employment were the most important variables in the prevalence of COVID-19 in patients with multiple sclerosis in our study.
Identifiants
pubmed: 36952532
doi: 10.1371/journal.pone.0283538
pii: PONE-D-22-22791
pmc: PMC10035930
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0283538Informations de copyright
Copyright: © 2023 Sedighi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Mult Scler Relat Disord. 2021 Jun;51:102886
pubmed: 33744758
Neurol Neuroimmunol Neuroinflamm. 2020 Jul 9;7(5):
pubmed: 32646885
Mult Scler Relat Disord. 2022 Jan;57:103335
pubmed: 35158427
Eur J Neurol. 2021 Oct;28(10):3384-3395
pubmed: 33340215
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Ann Neurol. 2022 Jan;91(1):89-100
pubmed: 34687063
Chest. 2020 Oct;158(4):1364-1375
pubmed: 32533957
Environ Res. 2018 May;163:43-52
pubmed: 29426027
eNeurologicalSci. 2021 Mar;22:100299
pubmed: 33313429
Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):
pubmed: 29440325
Mult Scler Relat Disord. 2020 Aug;43:102195
pubmed: 32460086
Best Pract Res Clin Anaesthesiol. 2021 Oct;35(3):293-306
pubmed: 34511220
Travel Med Infect Dis. 2020 Nov - Dec;38:101904
pubmed: 33137491
Hum Vaccin Immunother. 2022 Dec 31;18(1):2041945
pubmed: 35201963
Lancet Neurol. 2020 Jun;19(6):481-482
pubmed: 32359409
Neurol Neuroimmunol Neuroinflamm. 2021 May 20;8(4):
pubmed: 34016734
Mult Scler Relat Disord. 2022 Jan;57:103363
pubmed: 35158433
Arch Iran Med. 2020 Apr 01;23(4):283
pubmed: 32271605
Mult Scler. 2020 Sep;26(10):1163-1171
pubmed: 32772807
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
J Med Virol. 2021 Mar;93(3):1314-1319
pubmed: 33044760
J Clin Med. 2020 Dec 16;9(12):
pubmed: 33339436
Hum Vaccin Immunother. 2022 Dec 31;18(1):1981086
pubmed: 34614383
BMC Infect Dis. 2022 May 18;22(1):476
pubmed: 35585518
Int J Cardiol Heart Vasc. 2020 Jun 03;29:100557
pubmed: 32550259
Mult Scler. 2020 Dec;26(14):1816-1821
pubmed: 33174475
Basic Clin Neurosci. 2020 Mar-Apr;11(2):201-206
pubmed: 32855779
Prospects (Paris). 2020;49(1-2):91-96
pubmed: 32313309
Neurol Sci. 2020 Sep;41(9):2315-2316
pubmed: 32638135
Mult Scler Relat Disord. 2020 Jul;42:102193
pubmed: 32420011
Mult Scler Relat Disord. 2020 Sep;44:102372
pubmed: 32650121
Mult Scler Relat Disord. 2021 Sep;54:103163
pubmed: 34325399
Int Immunopharmacol. 2021 Dec;101(Pt B):108351
pubmed: 34801416
JAMA Neurol. 2020 Feb 1;77(2):184-191
pubmed: 31589278